bladder tumor. Malignant neoplasm of bladder
Conditions
Interventions
Intervention 1: 5 mg docetaxel in 40cc normal saline and 120mg BCG in 100cc normal saline intravesical with foley 18Fr, weekly to for 6 weeks. Intervention 2: 120mg BCG in 100cc normal saline intraves
Treatment - Drugs
5 mg docetaxel in 40cc normal saline and 120mg BCG in 100cc normal saline intravesical with foley 18Fr, weekly to for 6 weeks
120mg BCG in 100cc normal saline intravesical with foley 18Fr, weekly for 6 weeks
Sponsors
Urology Reaserch Center of Kermanshah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: age more than 18 years, presence of non-invasive bladder tumor (Ta,T1,CIS), grade>3, history of bladder cancer treatment, no previous radiotherapy to pelvic area, PMN>1500, HB > 8, normal LFT, Exclusion criteria: invasive or metastatic bladder tumor, previous treatment with docetaxel, allergy to docetaxel or BCG, history of VUR or ureteral stent placement, history of malignancy over last 2 years prior to the study except for Scc skin or non-invasive tumor of cervix, immunosuppression, pregnancy or breast feeding
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hematuria. Timepoint: at presentation. Method of measurement: subjective.;Other complication. Timepoint: at presentation. Method of measurement: subjective. | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrence of tumor. Timepoint: every 3 month. Method of measurement: cystoscopt. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Abdorrasoul Bardide
Kermanshah University of Medical Sciences
Outcome results
None listed